Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.44
+0.09003.83%
Post-market: 2.480.0400+1.64%19:48 EDT
Volume:1.28M
Turnover:3.08M
Market Cap:292.80M
PE:-2.32
High:2.47
Open:2.35
Low:2.35
Close:2.35
52wk High:3.23
52wk Low:0.9403
Shares:120.00M
Float Shares:104.94M
Volume Ratio:1.81
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.91
PE(LYR):-2.12

Loading ...

Fate Therapeutics Launches Phase 1/2 Complete Trial of FT839 Dual-CAR T Therapy in Rheumatoid Arthritis

Reuters
·
Yesterday

Fate Therapeutics announces clinical data from FT819 study

TIPRANKS
·
Sep 09

Fate Therapeutics Presents Phase 1 Data for Off-the-Shelf CAR-T FT819 in Systemic Lupus Erythematosus at CCR-West 2026

Reuters
·
Sep 09

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

GlobeNewswire
·
Sep 09

Fate Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat on FT819 Autoimmune CAR-T Program

Reuters
·
Sep 03

Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial

TIPRANKS
·
Sep 03

Fate Therapeutics intiates first patient in RECLAIM-LN trial

TIPRANKS
·
Aug 16

Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush

Dow Jones
·
Aug 14

Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26

THOMSON REUTERS
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis

THOMSON REUTERS
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewswire
·
Aug 14

Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives

Reuters
·
Aug 14

Analysts Conflicted on These Healthcare Names: Fate Therapeutics (FATE) and Mediwound (MDWD)

TIPRANKS
·
Aug 14

Fate Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate

Benzinga Earnings
·
Aug 13

Fate Therapeutics - Expects Operating Runway into 2028

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Q2 Operating Expenses USD 33.216 Million

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Don't Ignore The Insider Selling In Fate Therapeutics

Simply Wall St.
·
Aug 07

Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 07